Mydecine Innovations Group

The global psychedelic drugs market is set for rapid expansion, with projections forecasting growth from $4.88 billion in 2023 to $10.2 billion by 2028, according to The Business Research Company. With a compound annual growth rate of 16.1%, this rise is largely driven by increased awareness of...

Entheon Biomedical Corp. announced the launch of a psychedelics genetic test kit last week through its wholly owned subsidiary HaluGen Life Sciences Inc. The launch represents the first revenue stream for the company, said CEO Timothy Ko. The test will serve as a pre-screening platform...

Mydecine Innovations Group (OTC: MYCOF), a Denver-based psychedelics research company, announced its four lead novel drug candidates on Wednesday. The company plans to present the candidates at Pre-Investigational New Drug meetings with the FDA and Health Canada, a necessary step in obtaining...

Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit.  The proceeds...

In recent years mushrooms left their dark, hidden habitats to jump into the spotlight of consumer markets. A hunger for natural foods and wellness products propelled consumers to explore the realm of fungi as a source of nutrition and wellness, as well as a means to achieving physical and mental...

MAPS Gets $30M In Funds To Conclude MDMA Research The Multidisciplinary Association for Psychedelic Studies recently completed a fundraising of $30 million. The funds will help MAPS finish the NGO’s ongoing research for MDMA-assisted psychotherapy in the treatment of post-...